Search results
Novavax seeks EMA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 1 day agoNovavax , Inc. (NASDAQ:NVAX) has filed for a type II variation of existing Marketing Authorization...
COVID summer guide: How to navigate symptoms, variants and vaccines this season amid rising cases
Yahoo Life· 6 hours agoWho should wait and who should get vaccinated now? The CDC advises that everyone age 5 and older...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 4 days agoNovavax stock isn't a buy. Savvy investors are encouraged to buy a stock after it breaks out of a...
Novavax executive Dubovsky sells over $200k in company stock By Investing.com
Investing.com· 5 days agoNovavax Inc. (NASDAQ:NVAX) has reported recent stock transactions by President of Research and...
Novavax director James Young sells shares worth over $100k By Investing.com
Investing.com· 4 days agoJames F. Young, a director at Novavax Inc. (NASDAQ:NVAX), has sold a total of 7,500 shares of the...
The ‘new normal’ for Covid — and tropical diseases
Politico· 6 hours agoIT’S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. We’re doing our best to dodge the summer colds descending upon D.C. — how about you? Send news and tips to David Lim ([email ...
COVID is bouncing back this summer. Here’s what to know
Los Angeles Times· 8 hours agoSummer just started, but California’s not-too-surprising seasonal COVID bump is already going...
FDA advises vaccine manufacturers to make COVID-19 booster targeting KP.2 strain
ABC Action News Tampa Bay· 1 day agoThe FDA has issued an updated recommendation for the fall COVID-19 vaccine formula. "Coverage in the...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 5 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 days agoThat compares to 55.6% for Keytruda alone. Earlier in the year, one analyst called results from the...